A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Inclusion Criteria: * Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC) * Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team) * Child-Pugh score of 5 or 6 (ie, Child-Pugh A) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: * Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC * Prior allogenic stem cell or solid organ transplantation * Untreated symptomatic central nervous system (CNS) metastases * Clinically significant ascites as defined by: i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment Other protocol-defined inclusion/exclusion criteria apply